- Home
- FLC vs IKT Comparison
FLC vs IKT Comparison
Compare FLC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | IKT |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 201.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLC | IKT |
|---|---|---|
| Price | $18.02 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 37.8K | ★ 681.1K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.62 | $1.33 |
| 52 Week High | $15.45 | $3.32 |
Technical Indicators
Market Signals| Indicator | FLC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 72.04 | 52.14 |
| Support Level | $17.57 | $1.57 |
| Resistance Level | $17.84 | $1.72 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 92.47 | 83.67 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.